Market Place
Sourcing Support
Enforcement Report - Week of November 27, 2024
27 Nov 2024 //
FDA
Padagis Donates 15K Naloxone Units to Combat Overdose on Campuses
19 Nov 2024 //
PR NEWSWIRE
Padagis Generic Loteprednol Etabonate Receives Approval in U.S
10 Jul 2024 //
FDA
Padagis` Generic Azelastine Hydrochloride Receives Approval in the U.S.
08 May 2024 //
FDA
Sol-Gel`s Collaboration Partner File ANDA Drug Product Generic to Zoryve® Cream
01 Apr 2024 //
GLOBENEWSWIRE
Enforcement Report - Week of December 13, 2023
13 Dec 2023 //
FDA
Enforcement Report - Week of November 8, 2023
08 Nov 2023 //
FDA
Padagis` Generic Teriparatide Receives Approval in the U.S.
01 Nov 2023 //
FDA
Padagis Announces The Launch Of Brinzolamide Ophthalmic Suspension
13 Oct 2023 //
PR NEWSWIRE
Padagis` Generic Halobetasol Propionate Receives Approval in the U.S.
11 Aug 2023 //
FDA
Padagis Announces The First Launch Of An Over-The-Counter Naloxone Nasal Spray
08 Aug 2023 //
PR NEWSWIRE
Padagis Announces Acquisition Of 17,000 Square Meter Facility In Yerucham
20 Jul 2023 //
PR NEWSWIRE
Padagis Announces First Generic OTC Approval Of A Naloxone Nasal Spray Product
19 Jul 2023 //
PR NEWSWIRE
PADAGIS ANNOUNCES TWO FIRST-TO-FILE ANDA SUBMISSIONS
15 Jun 2023 //
PR NEWSWIRE
PADAGIS ANNOUNCES FDA APPROVAL OF A-RATED GENERIC VERSION OF UCERIS
28 Apr 2023 //
PR NEWSWIRE
Enforcement Report - Week of March 22, 2023
22 Mar 2023 //
FDA
Alcon Sues Padagis to Block Copies of Simbrinza Eye Drops (1)
01 Nov 2022 //
BLOOMBERGLAW
Padagis` Generic Halobetasol Propionate Receives Approval in the U.S.
17 Oct 2022 //
FDA
Moberg Pharma and Padagis sign agreement for MOB-015 in Israel
04 Aug 2022 //
PRNEWSWIRE
Padagis Generic Mupirocin Calcium Receives Approval in the U.S.
03 Aug 2022 //
FDA
Letter to Pharmacists concerning red dye #40
02 Aug 2022 //
PRESS RELEASE
Padagis Announces 3 Major Product Launches
21 Jun 2022 //
FDA
Padagis`s Generic Naloxone Hydrochloride Receives Approval in US
21 Jun 2022 //
FDA
Padagis` Generic Betamethasone Dipropionate Receives Approval in the U.S.
12 Apr 2022 //
FDA
Padagis Announces the FDA Approval and Launch of an AB Rated Generic Version of Tobradex® Ophthalmic Suspension
21 Mar 2022 //
PRESS RELEASE
Padagis` Generic Tobramycin and Dexamethasone Receives Approval in the U.S.
11 Feb 2022 //
FDA
Enforcement Report - Week of January 19, 2022
19 Jan 2022 //
FDA
Padagis Issues Voluntary Nationwide Recall for Nitroglycerin Lingual Spray
27 Dec 2021 //
FDA
Padagis Announces The First-to-Market Launch Of An AB Rated Generic Zomig
16 Nov 2021 //
PRNEWSWIRE
Padagis Launches AB Rated Generic Version Of Zomig Nasal Spray
16 Nov 2021 //
PRNEWSWIRE
Sol-Gel Announces Sale of Generic Dermatology to Partner Padagis for $21 M
04 Nov 2021 //
YAHOO
Sol-Gel Technologies Reports Third Quarter 2021 Financial Results
04 Nov 2021 //
GLOBENEWSWIRE
Sol-Gel to Partner Padagis for $21M
04 Nov 2021 //
GLOBENEWSWIRE
Padagis Announces The FDA Approval And Launch Of An AB Rated GenericOf Doxil®
21 Oct 2021 //
PRNEWSWIRE
Padagis Starts Life Post-Perrigo With Eucrisa Challenge
12 Oct 2021 //
PHARMAINTELLIGENCE
VYNE THERAPEUTICS Management`s Discussion and Analysis of Financial Condition
11 Oct 2021 //
MARKETSCREENER
Padagis Confirms First-to-File Patent Challenge For Generic Version Of Eucrisa®
28 Sep 2021 //
PRNEWSWIRE
Law firm trio directs GE’s bet on surgical tech company BK Medical
24 Sep 2021 //
REUTERS
Patent Filings Roundup: PTAB Denies Lash Company PGR over ITC Investigation
19 Aug 2021 //
IPWATCHDOG
VYNE Therapeutics Reports Second Quarter 2021 Financial Results
12 Aug 2021 //
GLOBENEWSWIRE
Altaris Capital Partners’ $1.55 Billion Acquisition of Padagis
10 Jul 2021 //
GLOBALLEGALCHRONICLE
Perrigo Closes $1.5B Sale of Generic Prescription Drugs Business
06 Jul 2021 //
POWDERBULKSOLIDS
